Company Description
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation.
The company's drug candidates include AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as Crohn's disease; Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome; and AVTX-008, a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein.
It also develops AVTX-803, a L-fucose monosaccharide therapy for treatment of Leukocyte Adhesion Deficiency Type II.
The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021.
Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
| Country | United States |
| Founded | 2011 |
| IPO Date | Oct 15, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 19 |
| CEO | Dr. Garry A. Neil M.D. |
Contact Details
Address: 540 Gaither Road, Suite 400 Rockville, Maryland 20850 United States | |
| Phone | 410-522-8707 |
| Website | avalotx.com |
Stock Details
| Ticker Symbol | AVTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001534120 |
| CUSIP Number | 05338F108 |
| ISIN Number | US05338F3064 |
| Employer ID | 45-0705648 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Garry A. Neil M.D. | Chairman of the Board, President and Chief Executive Officer |
| Christopher Ryan Sullivan | Chief Financial Officer and Head of Investor relations |
| Dr. Solomon H. Snyder M.D. | Founder and Chairman of Scientific Advisory Board |
| Dr. Barbara S. Slusher Ph.D. | Founder and Member of Scientific Advisory Board |
| Dr. Lisa Hegg Ph.D. | Senior Vice President of Program Management, Corporate Infrastructure and Clinical Operations |
| Colleen Matkowski | Senior Vice President of Global Regulatory Affairs and Quality Assurance |
| Dr. Dino C. Miano Ph.D. | Senior Vice President of CMC and Technical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 9, 2024 | D | Notice of Exempt Offering of Securities |
| Apr 5, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Mar 29, 2024 | 10-K | Annual Report |
| Mar 29, 2024 | 8-K | Current Report |
| Mar 28, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 28, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |